https://www.selleckchem.com/pr....oducts/bay-2416964.h
The objective of this retrospective study was to evaluate the outcome of dogs when grade II mast cell tumour (MCT) with low mitotic index (MI) and high Ki67 were treated with adjuvant lomustine. Client owned dogs with spontaneously occurring disease treated with adjuvant chemotherapy for grade II mast cell tumour with low MI (≤5/10HPF) and high Ki67 (1.8%) with no evidence of metastatic disease at presentation. Lomustine was administered every 3 weeks with three or four planned cycles. Response to treatment was assessed by regul
Aimer
Commentaire
Partagez
